TB-500 Human Studies: Has the Peptide Actually Been Tested in People?

Search for "TB-500 human studies" and most results eventually cite a real clinical trial: a Phase 1 safety study, a Phase 2 wound-healing trial, or a Phase 3 program for dry eye. What almost none of those results mention is that the molecule tested in those trials is not the same substance sold online as TB-500. This is the central confusion running through nearly every TB-500 marketing claim, and untangling it requires separating two different peptides that share a family history but are not interchangeable.

Independent laboratory analysis has identified the substance actually sold as TB-500 as Ac-LKKTETQ, a synthetic, N-acetylated seven-amino-acid fragment corresponding to residues 17 through 23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein. Review the laboratory identification of TB-500 as the Tβ4 17-23 fragment. The fragment is roughly one-fifth the mass of the full protein. Nearly every human clinical trial discussed in connection with TB-500, and cited below, was conducted on the full-length protein, not the small fragment. The question this article answers is a narrow and specific one: has the actual substance called TB-500 ever been administered to a person in a real clinical study? The evidence says no.

Human Studies Administering TB-500 Itself

A 2026 scoping review in Applied Sciences systematically searched PubMed, Europe PMC, and ClinicalTrials.gov through March 2026 for every study evaluating Tβ4, TB-500, or a related derivative in tissue healing and musculoskeletal repair. Of 1,772 records identified, 80 met the eligibility criteria. Of those 80 studies, exactly one was coded as direct TB-500 evidence, and that single study was a mixed, laboratory-based experiment centered on metabolite profiling and fibroblast wound-healing screening, not a human administration trial. Review the scoping review of TB4 and TB-500 in tissue healing and musculoskeletal repair. In other words, the single most comprehensive literature map assembled on this topic found zero human clinical studies of the actual TB-500 fragment. This matches the FDA's own review, which has reported that it has not identified human exposure data for drug products containing the Tβ4 LKKTETQ fragment sold as TB-500. AlphaMD's TB-500 benefits and risks overview covers this FDA finding in more detail.

Human Studies Involving Full-Length Thymosin Beta-4

The same scoping review found that 70 of the 80 included studies, 87.5 percent, evaluated full-length Tβ4 rather than TB-500 or a fragment, and that 19 of the 80 studies overall were human studies. Those human studies were concentrated almost entirely in two areas that have nothing to do with the tendon and muscle injuries the Wolverine stack and similar products are marketed for: ocular and corneal applications, where every included human study involved Tβ4, and wound and skin applications. Direct musculoskeletal tissue categories such as tendon, ligament, and muscle were sparsely represented in the entire 80-study literature map, and almost none of that sparse coverage was human data at all. A real, substantial body of human Tβ4 research exists. It was built almost entirely around different molecules, different formulations, and different medical conditions than the ones used to sell TB-500 for injury recovery.

Topical Thymosin Beta-4 Research

RegeneRx Biopharmaceuticals developed RGN-137, a topical gel formulation of full-length Tβ4, and RGN-259, an eye-drop formulation, and both have gone through real, registered human trials.

Epidermolysis bullosa: A randomized, double-blind, placebo-controlled Phase 2 trial tested topical RGN-137 gel, at three concentrations, in patients with epidermolysis bullosa, a genetic skin-blistering disease, with adverse events as the primary outcome and wound healing as a secondary outcome. The trial enrolled 30 patients but was ultimately terminated early because of limited patient availability and expiration of the study drug supply, not because of a safety finding. Review the Phase 2 thymosin beta-4 epidermolysis bullosa trial record.

Pressure ulcers and venous stasis ulcers: RGN-137 completed two separate Phase 2, randomized, double-blind, placebo-controlled trials, one in 72 patients with chronic Stage III or IV pressure ulcers and one in 73 patients with venous stasis ulcers, each applying topical gel daily for up to 84 days. Both trials met their primary safety objective, with no drug-related serious adverse events at any of the three tested concentrations. Neither trial met its secondary efficacy objective. In the pressure ulcer trial, the mid-dose group showed a faster initial onset of wound healing than placebo, but the difference was not statistically significant. In the venous stasis ulcer trial, about one-third of mid-dose patients achieved complete healing compared to 24 percent on placebo, a difference the company's own reporting and the peer-reviewed publication both describe as not statistically significant. Review the peer-reviewed report of the venous stasis ulcer trial.

Dry eye and neurotrophic keratopathy: RGN-259 eye drops went through three Phase 3 trials (ARISE-1, ARISE-2, and ARISE-3) for dry eye disease, the largest, ARISE-3, enrolling 700 patients. ARISE-3 did not meet either of its two primary outcome measures, corneal staining and ocular discomfort at day 15, but it did show a statistically significant improvement in ocular grittiness and several other pre-specified secondary symptom endpoints compared to placebo. Post-hoc analysis pooling all three Phase 3 trials reported additional improvements in certain sign and symptom measures. RGN-259 separately received FDA orphan drug designation for neurotrophic keratopathy, a rare corneal condition, based on a Phase 3 trial in a small number of patients.

Every one of these trials used a topical gel or an eye drop, applied directly to skin or the ocular surface. None involved an injection, and none treated a tendon, ligament, or muscle injury.

Injectable or Systemic Thymosin Beta-4 Research

The closest human research gets to the injectable, systemic use case that TB-500 is actually marketed for is RGN-352, RegeneRx's injectable Tβ4 formulation developed for cardiac and neurological indications, and even this research stops well short of showing a treatment benefit in patients.

Two independent Phase 1 trials have tested intravenous full-length Tβ4 in healthy volunteers. A 2010 study gave 40 healthy subjects ascending single intravenous doses from 42 to 1,260 milligrams, followed by 14 days of daily dosing, and reported the drug was well tolerated with no dose-limiting toxicities. Review the Phase 1 intravenous thymosin beta-4 safety study. A separate, independent first-in-human trial conducted in China in 2021 gave a recombinant version of the peptide to 84 healthy volunteers across seven ascending single-dose and three multiple-dose cohorts, again finding the drug well tolerated with no serious adverse events. Review the independent Phase 1 recombinant thymosin beta-4 trial. Both trials measured safety, tolerability, and pharmacokinetics in healthy people, not effectiveness in injured or ill patients.

A Phase 2 trial of RGN-352 was registered to test safety and efficacy in patients having a heart attack during angioplasty, a real step toward testing systemic Tβ4 in a patient population. That trial, however, was withdrawn and never initiated. As of today, injectable, systemic Tβ4 has completed Phase 1 safety testing in healthy volunteers and has not advanced into a completed efficacy trial in patients, for cardiac disease, neurological injury, or any other indication. This is the human research base closest in spirit, injected, systemic, intended to work throughout the body, to how TB-500 is actually used, and it still stops at Phase 1 safety data in healthy people using a different, much larger molecule.

Animal Studies Involving the LKKTETQ Fragment

Direct research on the actual TB-500 fragment, as opposed to the full Tβ4 protein, is sparse even in animals. One study found that the LKKTETQ sequence promoted dermal wound repair in aged and diabetic mice, a genuine preclinical signal, though a positive result in mice does not establish that the same fragment, injected into a person, safely accelerates healing. Review the animal wound-healing study of the LKKTETQ fragment. Separately, anti-doping researchers have developed methods to detect the fragment and its metabolites in horses given TB-500, confirming that the substance is absorbed and metabolized in a living animal, though these are analytical detection studies, not efficacy or safety trials. The 2026 scoping review discussed above found only four of its 80 included studies, across all species, focused specifically on TB4 derivatives or fragments rather than the full-length protein, underscoring how little dedicated research exists on the fragment actually sold as TB-500.

Claims Based Only on Online Experience Reports

In the absence of clinical trials, most of what circulates online about TB-500's effects in people comes from self-reported experiences on forums and vendor review pages: mild flu-like symptoms after the first few injections, injection-site redness or irritation, and occasional headache or fatigue. These reports may describe something real, but they cannot establish how common a reaction is, what caused it, or whether it reflects the peptide itself rather than a contaminant. Unregulated peptide products have documented, meaningful rates of bacterial endotoxin contamination, and most people posting these reports are simultaneously using other peptides, supplements, or rehabilitation protocols, which makes it impossible to attribute any effect, positive or negative, to TB-500 specifically. A forum thread is not a substitute for the clinical trial that has never been run.

The Bottom Line

The most rigorous available literature map found exactly one study anywhere directly evaluating the substance called TB-500, and that study was a laboratory experiment, not a human trial. The FDA has separately reported finding no human exposure data for drug products containing this fragment. A genuine, multi-decade human research program does exist for thymosin beta-4, the larger, related protein, spanning topical wound gels, eye drops for dry eye and neurotrophic keratopathy, and Phase 1 safety studies of an intravenous formulation, but that program has never advanced past healthy-volunteer safety testing for systemic use, has never targeted a tendon, ligament, or muscle injury, and tested a molecule roughly five times larger than the one actually sold as TB-500. Citing any of that research as evidence that TB-500 works, or is even safe, means citing studies of a different molecule tested for different conditions through different routes of administration. As of today, the peptide actually sold as TB-500 has not been tested in a completed human clinical trial for any indication.

For a closer look at TB-500's proposed benefits, documented risks, and regulatory status, see AlphaMD's TB-500 benefits, risks, and side effects overview, and for a look at the popular combination of TB-500 with another unproven peptide, see AlphaMD's evidence review of the BPC-157 and TB-500 "Wolverine stack".

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. TB-500 is not currently an FDA-approved drug. Speak with a licensed medical provider before using any medication, peptide, supplement, or injectable product.